• The once-daily dosing of tinzaparin provides an advantage over other low molecular weight heparins.
• The recommended age-dependent doses of tinzaparin in children have not previously been validated.
• Once-daily administration of tinzaparin is a safe and effective treatment of childhood thrombosis.
• Recommended doses are appropriate but monitoring may be required due to inter-individual variation.
Summary. Background: The recommended starting doses of tinzaparin for the treatment of thrombosis in children have not previously been validated. There are few data to support the efficacy and safety of once-daily tinzaparin dosing in children with thrombosis. Objectives: To investigate the use of tinzaparin for the treatment of childhood thrombosis, and to evaluate the age-dependent dosing recommendations and define outcomes in terms of efficacy and safety. Methods: This was a retrospective cohort study of children aged 0 to < 16 years treated for thrombosis at a large teaching hospital in the UK between 2008 and 2015. Medical records were reviewed to evaluate tinzaparin dosing, anti-activated factor X (FXa) levels, and patient outcomes. Results: Seventy-nine children were identified as having received tinzaparin. Dosing information was available for 57. Younger children required higher doses to reach a therapeutic level. The therapeutic dose requirement varied within age groups, supporting the use of anti-FXa monitoring. Over a median follow-up of 35 months, there were 13 (16%) bleeding episodes (two major; seven clinically relevant but non-major; and four minor). There were two (3%) recurrent episodes of thrombosis. Children were treated for a median duration of 3 months, and the majority (86%) remained on tinzaparin for the duration of their anticoagulant ther
Introduction
Owing to difficulties in the administration of oral coumarins, childhood thrombosis is frequently treated with low molecular weight heparin (LMWH) [1, 2] . In comparison with other preparations, for which a twice-daily dosing regimen is used, tinzaparin has the advantage of once-daily administration. Current age-dependent dosing recommendations for tinzaparin are based on a single study of 35 children with small numbers in each age group: the 0-2-month age group included 10 individuals; the 2-12-year age group included eight individuals; the 1-5-year age group included six individuals; the 5-10-year age group included four individuals; and the 10-16-year age group included seven individuals. Individuals were followed up for a relatively short period of time, either 3 months or until they completed anticoagulation (whichever was sooner), providing data for a median follow-up of 3 months [3] . These data have not been validated in an independent cohort.
The primary aim of this study was to determine whether the recommended age-dependent starting doses are appropriate to achieve therapeutic anticoagulation in a timely manner. A secondary aim was to assess the safety and efficacy of once-daily tinzaparin for the treatment of childhood thrombosis.
Methods

Patient selection
Consecutive children who were anticoagulated with tinzaparin at the Newcastle upon Tyne Hospitals NHS Foundation Trust between January 2008 and October 2010 were identified retrospectively from a hospital database. Children aged 0 to < 16 years were included. All were treated with once-daily tinzaparin, with the aim of achieving therapeutic anticoagulation. Although the majority of individuals were treated for a thrombotic event, either venous or arterial, individuals who required therapeutic anticoagulation for other indications were also eligible for inclusion.
Dosing and monitoring of tinzaparin
The institutional recommendation for initial tinzaparin dosing was based on the age-dependent recommendations made by Kuhle et al. and published in the American College of Chest Physicians guidelines: age 0 to < 2 months, initial dose of 275 U kg
À1
; age 2 to < 12 months, initial dose of 250 U kg
; age 1 to < 5 years, initial dose of 240 U kg À1 ; age 5 to < 10 years, initial dose of 200 U kg À1 ; and age 10 to < 16 years, initial dose of 175 U kg À1 [3, 4] .
It was recommended that peak anti-activated factor X (FXa) activity was measured 3 h after administration of the second dose. Anti-FXa activity was measured by use of the automated coagulation analyser ACL TOP CTS (Instrumentation Laboratory, Lexington, MA, USA) and anti-FXa reagents obtained from Instrumentation Laboratory (Bedford, MA, USA). The assay uses endogenous antithrombin, and dextran sulfate is included in the reaction mixture to reduce the influence of heparin antagonists such as platelet factor 4. The dose of tinzaparin was adjusted by increments of 10-20% to achieve and maintain anti-FXa activity within the therapeutic range. An anti-FXa activity of 0.5-1.0 IU mL À1 was considered to be therapeutic. Once therapeutic levels had been reached, anti-FXa activity was not tested routinely unless clinically indicated.
Collection of outcome data
Medical notes and imaging records were reviewed for details regarding site of thrombosis, duration of anticoagulant therapy, thrombus resolution, recurrent thrombosis, bleeding episodes, and long-term consequences, including post-thrombotic syndrome. Bleeding was classified according to ISTH criteria: major (fatal bleeding, a decrease in hemoglobin of ≥ 20 g L À1 in 24 h, or bleeding that is retroperitoneal/pulmonary/intracranial/ involves the central nervous system or requires surgical intervention in an operating suite); clinically significant non-major (need for blood product transfusion or intervention not in an operating suite); or minor (bleeding that does not fulfil the above criteria, including menstrual bleeding requiring a medical consultation) [5] .
Statistics
MINITAB software was used to analyze the data. Log transformation of therapeutic dose was performed and square root of duration to therapeutic dose was calculated, in order to approximately normalize the data. The values were compared between the five age groups by the use of a one-way ANOVA. Tukey's multiple comparison procedure was then used to identify which groups were different at a nominal P-value of < 0.05. t-Tests were used for post hoc contrasts. The proportions of individuals whose starting dose was within 10 U kg À1 of the recommended dose were compared between age groups by the use of chi-square tests. Levene's test was used to compare the within-group variability between age groups.
Results
Seventy-nine cases were identified, 48 (61%) of whom were male. The median age was 3 years (range: 0-15 years), and the number of individuals within each age range was as follows: 0 to < 2 months, nine individuals; 2 to < 12 months, 14 individuals; 1 to < 5 years, 23 individuals; 5 to < 10 years, nine individuals; and 10 to < 16 years, 24 individuals. The median follow-up was 36 months (range: 1-117 months).
Site of thrombosis
The most frequent thromboses were lower-limb deep vein thrombosis (DVT) and cerebral venous sinus thrombosis (Table 1) . Thirteen individuals had thrombosis in multiple locations, and 34 thrombotic events were related to a central venous access device (CVAD). One individual did not have a thrombosis but required therapeutic anticoagulation as thromboprophylaxis for a vertebral artery dissection. At least one identifiable provoking factor was present in the majority of cases (97%).
Initial and maintenance tinzaparin dosing
Data on tinzaparin dosing were analyzed for 57 cases. The remaining individuals were excluded from the analysis for the following reasons: six who received twicedaily dosing of tinzaparin at the initiation of anticoagulant therapy, 15 for whom there were insufficient dosing data, and one who had severe renal impairment (in this case, 75% of the recommended dose was given). In those who received twice-daily dosing, the recommended daily dose was halved and administered in two injections 12 h apart. This was performed in cases for which clinicians perceived a higher than normal risk of bleeding. Overall, 30 of 57 (53%) individuals started treatment within 10 U kg À1 of the recommended initial dose. The proportion in each age group that started treatment within 10 U kg À1 of the recommended dose was: 0-2 months, 33%; 2-12 months, 0%; 1-5 years, 63%; 5-10 years, 56%; and 10-16 years, 62% (P = 0.05). Those aged < 12 months were less likely than older individuals to be started within 10 U kg À1 of the recommended dose (25% versus 61%, P = 0.006). The younger individuals were more likely to be initiated on a dose lower than recommended. Therapeutic anti-FXa levels were achieved in 55 individuals (96%), and, of the two individuals who did not reach a therapeutic level, one had a starting dose 100 U kg À1 lower than recommended. Table 2 shows the median starting dose for each age group, and the dose at which therapeutic anticoagulation was achieved. Analysis of log therapeutic dose per body weight by age group gave a P-value of < 0.001 (R 2 = 37%), denoting significant differences. However, the three youngest age groups and the two oldest age groups did not differ significantly in mean value. Combining the three youngest age groups and the two oldest age groups gave a difference in log therapeutic dose of 0.29 (95% confidence interval 0.19-0.39, P < 0.001). Transforming back to the original scale gave average values of 275 U kg À1 in the three youngest age groups as compared with 205 U kg À1 in the two oldest age groups.
The median time needed to achieve therapeutic anticoagulation was 4 days (range: 1-29 days). There was no significant difference in the number of days needed to reach therapeutic anticoagulation between age groups (P = 0.32). There was also no significant difference in the number of days needed to reach therapeutic anticoagulation between those who started > 10 U kg À1 outside of the recommended dose and those who started with ≤ 10 U kg À1 (P = 0.54). Figure 1 shows the interindividual variability in the dose of tinzaparin that was required to achieve therapeutic anticoagulation within each age group. However, there was no significant difference in the variability of therapeutic dose per kilogram between age groups (P = 0.47).
Children were anticoagulated for a median of 3 months (range: 2 days to 9 months). Twenty-two (28%) individuals continued to receive treatment beyond 3 months, 50% of whom continued to receive tinzaparin. Anticoagulation was continued long term in eight individuals: tinzaparin in four, warfarin in three, and rivaroxaban in one. Two individuals treated for ≤ 3 months had their treatment changed to warfarin.
Outcomes
The median follow-up was 35 months (range: 1-117 months). Three individuals were lost to follow-up. There were three deaths during the follow-up period (4%). No deaths were attributable to the thrombotic event or complications of anticoagulant therapy.
Bleeding complications were recorded in 10 individuals (13%). There were of 13 (16%) bleeding episodes in total, with three individuals experiencing more than one. Bleeding sites included: CVAD site, three; hematuria, three; rectal, two; intracranial hemorrhage, one; pulmonary hemorrhage, one; menorrhagia, one; epistaxis, one; and Insuflon site, one. In five individuals, the anti-FXa level was subtherapeutic at the time of the bleeding episode, and in five it was not measured. There were no episodes of bleeding associated with known therapeutic or supratherapeutic levels. According to ISTH criteria, there were two major bleeds (intracranial hemorrhage and pulmonary hemorrhage), seven clinically relevant non-major bleeds, and four minor bleeds. All bleeding complications occurred within 7 months of the start of treatment, and four within 1 month. Interventions required for bleeding were: missed dose of tinzaparin, two; reduction to prophylactic dose of tinzaparin (75 U kg À1 daily), one; blood transfusion, one; and nasal packing for epistaxis, one. There were two episodes of recurrent thrombosis (3%). One individual with intracardiac thrombus developed a further arterial thrombus 17 days after starting anticoagulant therapy, and, a week later, developed a pulmonary embolism during a surgical thrombectomy. This individual started with a lower than recommended initiation dose, but achieved therapeutic anticoagulation within 1 day. The second occurred 3 months after the start of treatment for a CVAD-related neck vein thrombosis, at a time when anti-FXa activity levels were subtherapeutic.
Forty-two individuals developed thrombosis in an extremity or the vena cava. Seven of 42 (17%) had clinical signs of post-thrombotic syndrome, but all were asymptomatic: three individuals with upper-limb DVT had superficial venous distension of the upper limb or chest wall, and one of these also had disparity of upper arm circumference; four with lower-limb DVT had > 1-cm disparity of thigh circumference.
Discussion
These data support the current age-dependent dosing recommendations for tinzaparin in the therapeutic anticoagulation of children aged < 16 years [3, 4] . In both our cohort and that reported by Kuhle et al., 97% of children achieved therapeutic levels of tinzaparin with this approach [3] . Kuhle et al. reported a marginally shorter median time needed for therapeutic anticoagulation to be achieved (2 days) than in our cohort (4 days), most likely because of the measurement of anti-FXa activity only when clinically indicated in our cohort [3] . Younger children required higher weight-adjusted doses than older children, as is the case with other LMWHs [2] . There was interindividual variability in the dose of tinzaparin that was required to achieve therapeutic anticoagulation within each age group, as has been shown in previous pediatric studies of LMWHs [3, [6] [7] [8] [9] [10] [11] , supporting the need to monitor by the use of anti-FXa activity levels. In contrast to other studies, this variability was no greater within the younger age groups than within the older age groups [2, 3] . Previous work has also demonstrated that, although children aged < 5 years eliminate tinzaparin faster and require higher doses, they also tend to reach peak drug levels faster than older children [2, 3] . A recent review of tinzaparin dosing in a pediatric intensive care unit showed that higher than recommended doses were required in this particular clinical setting, and again supported the need for anti-FXa activity monitoring [12] . Tinzaparin has been shown to have a higher level of antiactivated FII (FIIa) activity than other LMWHs such as enoxaparin [13] . Previous work involving unfractionated heparin demonstrated that anti-FIIa activity can be affected by age, with the differences being more pronounced in younger children [14] .
There were no deaths related to thrombosis or anticoagulant therapy in our cohort. The relatively low mortality rate, as compared with previous published cohorts of children with thrombosis, may be attributable to bias in relation to the choice of anticoagulant: unfractionated heparin is used in preference to LMWH in our institution for complex, often postsurgical, cases, and these individuals may be at greater risk of death. The previous study by Kuhle et al. reported a similar rate of major bleeding (3%) to that in our cohort, defined as a drop in hemoglobin level of ≥ 20 g L À1 over 24 h, the need for red cell transfusion, or critical site bleeding (retroperitoneal, intracranial, intraocular, or intra-articular). Kuhle et al. reported a higher rate of thromboembolic recurrence (11%), although all recurrences occurred at a subtherapeutic level of anticoagulation [3] . The recurrence rate was comparably low in our cohort (3%), potentially because of the retrospective nature of the study and the lack of routine follow-up imaging. As is usually the case in children with thrombosis, the majority of events were 'provoked': this may also explain the low rate of recurrence in this study. A systematic review of LMWH use in children found similarly low rates of major bleeding and symptomatic recurrence as in our cohort [15] . A recent study investigated the use of tinzaparin in children who Age group Tinzaparin dose required to achieve therapeutic level (U kg -1 ) Fig. 1 . Once-daily tinzaparin dose required to achieve therapeutic anticoagulation.
had developed CVAD-related thrombus while undergoing regular hemodialysis. Ten individuals, aged between 7 months and 15 years, were identified, and the starting dose was not adjusted for age. There were no episodes of bleeding, but there was a higher rate of recurrence (10%), which may be explained by the need to maintain central venous access [16] . Other studies have confirmed the efficacy and safety of other LMWHs, such as enoxaparin and dalteparin [10, 11, 17, 18] . Tousovska et al. investigated the use of enoxaparin in 33 children undergoing cancer treatment. Despite the majority of cases experiencing thrombocytopenia, with a platelet count of < 20 9 10 9 L À1 , during treatment with enoxaparin, there were no cases of severe bleeding [19] . Prospective randomized controlled trials of anticoagulants are difficult to complete in the pediatric population, owing to the relatively low frequency of thrombosis. The first multicenter randomized controlled trial of treatment of venous thromboembolism in children compared the LMWH reviparin with unfractionated heparin and vitamin K antagonists. It closed early, owing to poor recruitment, but supported reviparin as an effective and safe treatment [20] . The current multicenter Kids-DOTT trial, the primary aim of which is to investigate a shortened duration of anticoagulation following venous thromboembolism in children, reported pilot/feasibility data after recruiting the first 100 participants. The majority were treated with LMWH, and the rates of symptomatic recurrence and clinically significant bleeding at 1 year of follow-up were 3.3% and 1.4%, respectively, again similar to what was found in this cohort [21] . Other studies investigating the use of direct oral anticoagulants, such as dabigatran and rivaroxaban, are using LMWH as one of the 'standard of care' comparators (ClincalTrials.gov NCT01895777; NCT02234843), and will hopefully add to our knowledge on the efficacy and safety of LMWH in the treatment of childhood thrombosis. Our data support a once-daily tinzaparin regimen as a safe and effective treatment for childhood thrombosis. We would suggest monitoring of anti-FXa levels for two doses following both initiation of therapy and a change of dose.
In terms of limitations, this was a retrospective cohort study that was limited to the use of the LMWH tinzaparin. In this cohort, anti-FXa activity levels were not routinely measured immediately following dose increments, limiting our ability to accurately measure the time taken to achieve therapeutic anticoagulation. This was likely to have been overestimated, as only 46% of the cohort started tinzaparin within 10 U kg -1 of the recommended dosage. A further limitation concerns how the tinzaparin was administered. Both prefilled syringes and vials were used, which may have altered the decisions made about dose increments. Within our institute, Insuflons are often used in children > 5 kg in weight, but, in other cases, daily injections are used: the presence of 'dead space' within the Insuflon may have had an impact on anti-FXa activity levels. In addition, previous studies have questioned the utility of anti-FXa activity monitoring for predicting the efficacy and safety of LMWH therapy in children [22] . Previous work has suggested that the addition of dextran sulfate to the anti-FXa activity assay used in this cohort may have exaggerated anti-FXa activity [23] .
A prospective study of tinzaparin use for the management of thrombosis in the pediatric population is required. In addition to recording rates of recurrence and bleeding episodes, it would be helpful to evaluate: the response to treatment as assessed by follow-up imaging at defined time points; the incidence of post-thrombotic syndrome measured by use of a validated scoring system; and an analysis of the impact of once-daily dosing on quality of life and cost.
Conclusion
Tinzaparin is a safe and effective treatment for childhood thrombosis. Younger patients require higher doses per kilogram of body weight. Owing to variability in response between individuals of a similar age, monitoring of antiFXa activity levels is required in order to ensure that therapeutic anticoagulation is achieved. 
